Launch week offerEnds in00h00m00s

annual Promonthly Pro

Andrew Perkins

Has grant

Professor of Blood Cancer Genomics

MONASH UNIVERSITY

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia Professors in Biochemistry Biochemistry professors in Australia

Recent Grants

Grant: Close

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis

Open Date: 2020-03-01

Close Date: 2025-12-01

Grant: Close

Development of Improved Biomarkers and Targeted Therapies for Myeloproliferative Neoplasms

Open Date: 2020-02-01

Close Date: 2022-10-01

Grant: Close

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

Open Date: 2020-02-01

Close Date: 2025-12-01

Grant: Close

A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients

Open Date: 2019-08-01

Close Date: 2024-12-01

Grant: Close

Improving survival in myelofibrosis

Open Date: 2019-01-01

Close Date: 2023-12-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (23)

Rabina Giri

The University of Queensland

AUSTRALIA

Andrew Perkins

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)

DOT1L provides transcriptional memory through PRC1.1 antagonism

Pathogenic<i> OTUD3</i> Mutations Predispose to Ulcerative Colitis Due to Barrier Dysfunction

Targeting enhancer RNAs to silence transcription

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Reduced PI3K(p110α) induces atrial myopathy, and PI3K-related lipids are dysregulated in athletes with atrial fibrillation.

Clinical utility of panel-based genetic sequencing for von Willebrand disease

KLF feedback loops in innate immunity.

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Variants leading to dysfibrinogenaemia in the fibrinogen α‐chain at residue Arg19 are not solely associated with bleeding, but also with thrombotic events—RESPONSE

Revisiting γ-globin gene repression by TR4

Single-cell transcriptomics reveals the cellular identity of a novel progenitor population crucial for murine neural tube closure

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.

Congenital fibrinogen disorders: Strengthening genotype–phenotype correlations through novel genetic diagnostic tools

A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X<sub>L</sub>/BCL-2 inhibition with navitoclax

Collaborators (23)

Rabina Giri

Ranjeny Thomas

Maya Koren-Michowitz

Rami Komrokji

Vikas Gupta

Stephen T. Oh

ROSA MARIA AYALA DIAZ

Andreas Reiter

Srdan Verstovsek

Yow Keat Tham

Ruby Lin

Sebastian Grosicki

Florian Heidel

Chris Van Geet

David Ross

Julie McMullen

James McFadyen

Daniel G Donner

Mary Frances McMullin

Tim Somervaille

Huyen Tran

Bianca Christine Bernardo

Emily Heikamp

Make your next move.